Sizling Stock Update: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

stock recommendation

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

B. Riley FBR Initiates Coverage On AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s stock to Buy with the price target of $9. This rating was issued on 10/23/18. The stock recently closed its previous session at $4.15 by showing a percentage change of 10.67% from its previous day closing price of $3.75.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in which Jefferies Upgrades AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to Buy by settling a price target of $8 on 10/15/18. Ladenburg Thalmann Reiterates the stock to Buy on 10/10/18 by stationing a price target of $10. Ladenburg Thalmann Initiates Coverage On the company’s stock to Buy on 8/16/18 by setting a price target of $7. Oppenheimer Initiates Coverage On AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to Perform with no specific Price Target.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) currently has a consensus Price Target of $7.8. While some analysts have a High Price target for the stock of $10 and a Low Price Target of $5.

Several sell side analysts reviewed their recommendations on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) where 1 analyst have rated the stock as Strong Buy, 3 analysts said it’s a Buy, 3 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.4. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) reported its Actual EPS of $-0.2/share. The analysts offering Earnings Estimates for the company were believing that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) could bring EPS of $-0.2/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus the company showed an Earnings Surprise of 0 Percent.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has a market capitalization of 251.49 Million. The stock traded with the volume of 3.54 Million shares in the last trading session. The stock touched its high share price of $5.03 on 10/15/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 03/07/18 as $1.65. The company has a 1 Year high price target of $8.2. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 11.57%. The Moving Average SMA50 is 21.56% while SMA200 is 48.14%.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is currently showing its ROA (Return on Assets) of -62.4%. The Return on Investment (ROI) is at -5.9% while it’s Return on Equity (ROE) value stands at 110.7%. The stock currently shows its YTD (Year to Date) performance of 104.94 percent while its Weekly performance value is 4.53%. The Monthly and Yearly performances are 5.06 percent and 107.5 percent respectively. The Relative Volume value measured for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is 1.58. The Average Volume (3 months) is 2.25 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ACRX has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 5.74 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.